Azenta Inc(AZTA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 6:22 PM ET (Korea 10/31 07:22)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.67 | Insider Own | 1.57% | Shs Outstand | 43.8M | Perf Week | 7.01% |
| Market Cap | 1.71B | Forward P/E | 81.8 | EPS next Y | 50.14% | Insider Trans | 1.53% | Shs Float | 43.1M | Perf Month | 13.28% |
| Enterprise Value | 1.44B | PEG | 7.53 | EPS next Q | 0.11 | Inst Own | 115.85% | Short Float | 12.44% | Perf Quarter | 30.72% |
| Income | -0.12B | P/S | 2.79 | EPS this Y | -37.64% | Inst Trans | -6.12% | Short Ratio | 5.65 | Perf Half Y | 56.8% |
| Sales | 0.61B | P/B | 1.13 | EPS next 5Y | 10.86% | ROA | -5.75% | Short Interest | 5.36M | Perf YTD | 17.44% |
| Book/sh | 34.51 | P/C | 5.21 | EPS past 3/5Y | 40.29% - | ROE | -7.04% | 52W High | -15.84% ($46.41) | Perf Year | 30.64% |
| Cash/sh | 7.49 | P/FCF | 173.19 | Sales past 3/5Y | 2.25% 8.85% | ROIC | -7.86% | 52W Low | 145.2% ($15.93) | Perf 3Y | -11.27% |
| Dividend Est. | - | EV/EBITDA | 36 | EPS Y/Y TTM | -9.38% | Gross Margin | 44.05% | Volatility(W/M) | 5.24% 7.27% | Perf 5Y | -66.46% |
| Dividend TTM | - | EV/Sales | 2.34 | Sales Y/Y TTM | 1.47% | Oper. Margin | -2.57% | ATR (14) | 2.13 | Perf 10Y | 200.46% |
| Dividend Ex-Date | 2021/12/2 | Quick Ratio | 2.21 | EPS Q/Q | 104.7% | Profit Margin | -20.02% | RSI (14) | 57.44 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.5 | Sales Q/Q | 11.97% | SMA20 | 3.86% ($37.61) | Beta | 1.49 | Target Price | $37.8 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/11/10 | SMA50 | 11.7% ($34.97) | Rel Volume | 0.95 | Prev Close | $41.27 |
| Employees | 3000 | LT Debt/Eq | 0.04 | EPS/Sales Surpr. | 40.6% 7.95% | SMA200 | 37.69% ($28.37) | Avg Volume(3M) | 0.95M | Price | $39.06 |
| IPO | 1995/2/2 | Option/Short | Yes/Yes | Trades | 10155 | Volume | 902,645 | Change | -5.35% |
🧬 Azenta (AZTA) is a healthcare company that provides biological sample management and storage, as well as genomic analysis services, which are essential for pharmaceutical and biotech research. From automated ultra-low-temperature storage equipment to gene sequencing and synthesis, along with sample repository operations, the company broadly supports the back-end infrastructure of new drug development.
Over the past 1 year, on the higher side
16% below its 1-year high.
Traded about as much as usual. That is 95% of its average volume.
Next earnings report: November 10
10 days to go.
AZTA has a sound balance sheet but weak earning power
Of every $100 in sales, $2.57 is lost.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -37.6% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $279. Peers typically go for $271. Compared with its own 1-year average, it is 39% cheaper now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -66.5%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 115.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #27 of 51 in the industry
Based on market cap of $2B.
FAQ
What kind of company is AZTA?
AZTA belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of AZTA?
The market cap of AZTA is approximately $1.7B, ranking 2,175 within its sector.
What is the 52-week high and low for AZTA?
AZTA has recorded a 52-week high of $46.41 and a low of $15.93.
